Retatrutide generally exhibits a favourable safety profile, with mild-to-moderate gastrointestinal symptoms being most common
When that happens, the goal is not perfect meals
Studies show patients may lose 10-15% of body weight over 6-12 months, but results vary
Since injectable peptide drugs require continuous and repeated administration, which causes patient discomfort and has a great effect on medication compliance, pharmaceutical efforts have been directed at improving the invasive administration of injectable formulations [9,10]
Estos datos requerirn actualizacin cuando comience la distribucin comercial
In 2011, Dandona had tried treating patients with Type 1 diabetes with a related but less effective medication, liraglutide